HCFA Expanding PET Medicare Coverage To Three More Cancer Indications
This article was originally published in The Gray Sheet
Executive Summary
Medicare will cover three additional indications for positron emission tomography (PET) in the diagnosis and management of cancer, the Health Care Financing Administration announced March 8.
You may also be interested in...
UCLA Requests Medicare Coverage Of PET Scans For All Oncology Indications
Positron emission tomography (PET) scans led to a "change in management" in 100% of 301 patients being diagnosed for breast cancer, according UCLA's analysis of published literature in a July 10 Medicare coverage request submitted to the Health Care Financing Administration.
UCLA Requests Medicare Coverage Of PET Scans For All Oncology Indications
Positron emission tomography (PET) scans led to a "change in management" in 100% of 301 patients being diagnosed for breast cancer, according UCLA's analysis of published literature in a July 10 Medicare coverage request submitted to the Health Care Financing Administration.
Positron Corporation
Private placement of 42.2 mil. shares of common stock raises $12.7 mil. About 21.5 mil. five-year warrants also were issued in connection with the financing. Proceeds will be used for manufacturing and marketing of the firm's Posicam postitron emission tomography scanners, as well as debt repayment and general corporate purposes. The funding follows Imatron's January purchase of a controlling interest in Positron and is in line with Imatron's plans to reactivate and recapitalize the dormant PET maker (1"The Gray Sheet" Feb. 1, p. 15). The capital infusion comes on the heels of recent favorable reimbursement recommendations for a broad range of PET procedures from the Health Care Financing Administration (2"The Gray Sheet" March 15, p. 20)